• Cathepsin B inhibitor CA-074: Practical Guide

  2026-08-26

  CA-074 (SKU A1926) provides a selective, nanomolar-range tool for separating cathepsin B activity from related cysteine proteases in biochemical and cell-based workflows. It is suitable for controlled studies of cancer metastasis, neurotoxicity reduction via cathepsin B inhibition, and immune response modulation, but its purified-enzyme potency should not be treated as a validated cellular dose or as evidence of broad cathepsin inhibition.

• Disulfiram in APC-Deficient CRC Assay Design

  2026-08-25

  Disulfiram can serve as a genotype-informed probe for studying APC-deficient colorectal cancer through ALDH2 inhibition, oxidative stress, and ASK1/JNK signaling. This guide translates the reference findings into practical assay decisions while distinguishing the CRC mechanism from disulfiram’s copper-dependent proteasome activity.

• Reserpine (N1867): Lab Workflow Guide

  2026-08-25

  Reserpine (SKU N1867) is a high-purity research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research. This guide covers identity checks, DMSO preparation, storage, and quality-control practices; the compound is for research use only and should not be used for diagnostic, therapeutic, or medical applications.

• Rucaparib: From Splicing State to PARP Assays

  2026-08-24

  Rucaparib and AG-014699 can do more than quantify PARP dependence: they can help connect DNA damage phenotypes with spliceosome state. This article translates recent SmD2 research into a biologically informed framework for cancer research, radiosensitization, and assay interpretation.

• AG-120 (Ivosidenib) in Mutant IDH1 Research

  2026-08-24

  AG-120, also called Ivosidenib, is an orally bioavailable inhibitor of mutant IDH1 that supports 2-hydroxyglutarate reduction and differentiation-focused AML research. Its strongest use is as a genotype-linked research tool, while resistance, IDH2 biology, and incomplete clinical translation define important limits.

• MK-5108 (VX-689): AURKA Assay Design

  2026-08-23

  MK-5108, also known as VX-689, enables selective Aurora A inhibition for mechanism-led cancer research. This guide connects its biochemical profile with retinoblastoma biology, model selection, and more interpretable cell and xenograft assays.

• FLCN Mutations and mRNA Rescue in BHD Syndrome

  2026-08-22

  A 2026 study identified a novel FLCN nonsense variant and supplied functional and co-segregation evidence that reclassifies p.W376R as pathogenic in two Chinese Birt-Hogg-Dubé families. Its cell-based mRNA rescue experiments restored folliculin expression and normalized mTORC1 dysregulation, providing a preliminary framework for protein-replacement research rather than a clinical therapy.

• AO/PI Double Staining Kit: Cell Viability Guide

  2026-08-22

  The AO/PI Double Staining Kit uses Acridine Orange Propidium Iodide staining to distinguish viable, apoptotic, and necrotic cells by fluorescence. Its dual-dye readout supports rapid cell viability assay workflows, but fluorescence categories require appropriate controls and should not be treated as a complete mechanistic diagnosis.

• Metformin and AMPK in Vocal Fold Fibrosis

  2026-08-21

  The reference study combines a rabbit vocal fold injury model with TGF-β1-stimulated fibroblasts to show that metformin reduces collagen accumulation and myofibroblast-associated markers through AMPK signaling. Its value lies in connecting metabolic pathway modulation with vocal fold scar biology while also identifying dose, timing, functional recovery, and translational questions that require further study.

• Cy3-dCTP for Direct Fluorescent DNA Labeling

  2026-08-20

  Cy3-dCTP enables direct enzymatic labeling of DNA and cDNA for PCR, Nick Translation, microarrays, blots, and in situ hybridization. This practical guide combines product-specific handling with a recent DNA-framework study to improve labeling consistency while separating validated workflows from forward-looking assay design.

• Baicalin Methyl Ester and Intestinal Barrier Protection

  2026-08-20

  The 2024 reference study shows that baicalin methyl ester attenuates LPS-induced intestinal barrier injury in mice and MODE-K epithelial cells by regulating the P65/TNF-α/MLCK/ZO-1 axis. Its integrated in vivo, in vitro, molecular docking, and immunoprecipitation evidence provides a useful framework for studying cytokine-driven tight-junction disruption, while the acute pretreatment design limits direct clinical extrapolation.

• Grazoprevir Hydrate: From Target to Assay

  2026-08-19

  Grazoprevir hydrate is a picomolar HCV NS3/4A protease inhibitor with a distinctive genotype-sensitive pharmacology. This assay-focused guide connects mechanism, translational evidence, pharmacokinetics, and practical experimental design.

• Sildenafil Citrate: PDE5 Workflows for Vascular Research

  2026-08-19

  Sildenafil Citrate enables controlled interrogation of cGMP-dependent vascular signaling, from PDE5 activity and smooth muscle relaxation to ERK1/ERK2 phosphorylation in PASMCs. This workflow-focused guide also shows how proteoform-resolved native mass spectrometry can expose interaction differences that conventional cell assays may miss.

• AO/PI Double Staining Kit: Practical QC Guide

  2026-08-18

  The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates viable, apoptotic, and membrane-compromised cells in one staining workflow. It is intended for in vitro cell analysis and should not be used as a standalone confirmation of cell-death pathways or for direct in vivo applications.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-18

  FITC-Concanavalin A (ConA) Conjugate provides a direct fluorescent readout for accessible α-D-glucose and α-D-mannose moieties on glycoproteins and glycolipids. It is intended for cell surface carbohydrate detection, immunofluorescence staining, tissue labeling, and flow cytometry—not for general protein staining or non-carbohydrate targets.

555 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page